Latest Biotech Startup Funding Rounds

Mithrl builds a scientific decision engine for biopharma and research teams. Its biomedical world model combines validated biological knowledge with each organization’s data, then uses AI agents and workflows to help scientists analyze experiments, assess hypotheses and accelerate drug-discovery decisions; the company is preparing its next-generation platform for broader deployment.

A clinical-stage biotechnology company developing an oral drug candidate for thyroid eye disease.

Circle Pharma discovers macrocycle medicines for cancer and other serious diseases using its MXMO platform, which combines computational, structure-based design with synthetic chemistry to create cell-permeable compounds against difficult protein targets. Its lead programs are investigational and at discovery or preclinical stages.

A precision-medicine company developing liquid-biopsy tests that interpret cell-free DNA signals for early disease risk assessment.

RegCell is developing cell therapies for autoimmune disease by epigenetically reprogramming pathogenic conventional T cells into stable regulatory T cells, aiming to restore immune tolerance without gene engineering; its platform is advancing toward clinical development.

ReEmerge is developing Cognitive Network Restoration Therapy (CNRT) for people with chronic cognitive impairment after brain injury. The treatment targets underactive but viable neural circuits in the central thalamus to restore function across disrupted brain networks; the company is advancing this restorative approach through clinical development.

Evvy combines at-home vaginal microbiome testing with clinician-reviewed results, personalized next steps and optional treatment and coaching for women’s health.

A biotechnology company developing antibody diagnostics and drug-discovery methods for difficult protein targets.

Ferm Labs develops fermentation-based flavour ingredients for food manufacturers, using fermentation science to deepen savoury taste and help reformulate products with less salt and fewer additives.

Shennon Biotechnologies is developing precision T-cell engager immunotherapies for solid tumors.